Medifast, Inc. (MED)

Score 3 (Mixed): Operating performance is still declining (FY2025 revenue -36% YoY; TTM net margin -8.08%), but liquidity is very strong (~$170M cash+investments and minimal debt per recent filings) and valuation is extremely low (EV/Sales 0.27; P/B ~0.66). This is investable mainly as a turnaround/value thesis and needs evidence of stabilization.

Dominant catalyst is the announced Q2-2026 earnings print (2026-08-03): a consensus EPS/revenue beat that popped the stock 12.8% and drew a Seeking Alpha rating upgrade, but revenue fell 28% Y/Y and FY26 guidance implies continued losses. The determinate sentiment delta is mildly negative (≈ -0.01 baseline to ≈ -0.08 scoring) with indeterminate retail, and a moderate red-flag cap applies (conflicting catalyst signals — two-sided media narrative).

MED is in a strong post-earnings uptrend: price 12.45 sits above SMA20 (11.73), SMA50 (10.98), SMA200 (11.15), EMA9 (11.98), EMA21 (11.61) and today's VWAP (12.39). ADX14 at 50.37 and rising alongside higher prices is a strong, well-participated UP trend (direction confirmed by the bullish moving-average stack, not a bearish read). MACD (0.35) is above its signal (0.29) and above zero with a positive histogram (0.06); RSI14 63.78 and Williams %R -21.71 are bullish but nearing overbought after the +28% run from 9.74 (08-03) to 12.45. The weak point is volume: 08-27 traded only ~13.7K shares versus 908K on the 08-04 earnings catalyst day, and the 20-day average dollar volume (~$2.18M) is far below the $5M floor. Trend + momentum score 4, but the thin tape disqualifies any trade.